ABSTRACT Ebola virus (EBOV) causes severe hemorrhagic fever in humans and other primates with a high case fatality rate. No approved drug or vaccine of EBOV is available, which necessitates better understanding of the virus life cycle. Studies on EBOV have been hampered because experimentations involving live virus are restricted to biosafety level 4 (BSL4) laboratories. The EBOV minigenome system has provided researchers with the opportunity to study EBOV under BSL2 conditions. Here, we developed a novel EBOV minigenome replicon which, to our knowledge, is the first EBOV cell culture system that can stably replicate and transcribe the EBOV minigenome. The minigenomic RNA harboring a Gaussia luciferase and hygromycinresistant marker can replicate for months in a helper cell stably expressing viral nucleoprotein (NP), viral protein 35 (VP35), VP30, and L proteins. Quantification of viral RNA (vRNA), cRNA, and mRNA levels of the EBOV minigenome demonstrated that the stable EBOV replicon had much-more-active minigenome replication than previously developed transient-transfection-based EBOV minigenome systems, which recapitulate viral primary transcription more than genome replication. Interestingly, minigenome replication in the stable EBOV replicon cells was insensitive to interferon treatment or RNA interference. Moreover, RNase digestion of the replicon cell lysates revealed the remarkably stable nature of the EBOV minigenomic vRNA ribonucleoprotein complex, which may help improve understanding of EBOV persistence in convalescent patients.
belonging to the family of Filoviridae, has a nonsegmented negative-strand RNA genome and produces enveloped virions (3) . The viral RNA genome, approximately 19 kb in length, encodes 8 major viral proteins: nucleoprotein (NP), viral protein 35 (VP35), VP40, VP30, VP24, glycoprotein (GP), soluble glycoprotein (sGP), and large protein (L), which is the RNA-dependent RNA polymerase (RdRp) (4) . NP, VP35, VP30, and L proteins bind viral RNA (vRNA) to constitute the ribonucleoprotein (RNP) complex, representing the minimal viral elements required for EBOV genome replication and transcription (5) .
Although there has been good progress in EBOV vaccine development (6) , no effective prophylactics or therapeutics has been approved for EBOV. The slow progress in EBOV research could be attributed at least partially to its status as a risk group 4 agent, which requires any experiments involving infectious virions to be conducted in only a few biosafety level 4 (BSL4) laboratories in the world (7) . In order to circumvent this limitation, various EBOV life cycle modeling systems have been developed to enable studies of EBOV under BSL2 conditions (8, 9) . To recapitulate viral replication and transcription, an EBOV minigenome system was established in which a reporter gene, encoding a product such as green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), or luciferase (Luc), is flanked by the minimal regulatory cis elements located at the two ends of viral genome essential for viral replication and transcription (10) . The most widely used EBOV minigenome system was generated by cotransfecting cells with 6 plasmids: 1 expressing the EBOV minigenome driven by the T7 promoter, another expressing T7 polymerase, and 4 others expressing NP, VP35, VP30, and L proteins, respectively (8, 9) . Upon delivery into the cytoplasm, the minigenome is encapsidated by NP and, through interactions with components of the polymerase machinery, primed for transcription and replication, leading to the reporter activity (11) . The success of EBOV replication by this approach is dependent upon the delivery of all 6 of the plasmids into a single cell, which demands high transfection efficiency and delicate stoichiometry among four viral proteins (5, 12) . In addition, the 6-plasmid transfection produces only transient replication and transcription of the EBOV minigenome. To improve the efficiency and reproducibility of this EBOV minigenome system, we generated an EBOV replicon system in which the minigenome can stably replicate and transcribe. This new replicon system represents a more efficient and relevant surrogate model for studying EBOV replication and for developing antivirals targeting viral replication under BSL2 conditions than the conventional transienttransfection-based minigenome systems.
RESULTS
In vitro transcribed EBOV minigenomic RNA can replicate and transcribe with the help of viral proteins. An EBOV minigenome was constructed in which the Gaussia luciferase (GLuc)-encoding gene was flanked by the leader and trailer sequences as well as the untranslated region (UTR) of NP and L genes, the cis elements essential for viral replication and transcription ( Fig. 1A and B) . To optimize the previously developed 6-plasmid transfection-based EBOV minigenome system, we first attempted to reduce the number of cotransfected plasmids by carrying out the transcription of the EBOV minigenome in vitro (Fig. 1B) . The in vitro transcribed EBOV minigenome (vRNA) was transfected into Huh7 cells alone; with three plasmids encoding NP, VP35, and VP30, respectively; or with four plasmids encoding NP, VP35, VP35, and L, respectively. The replication and transcription of the minigenome were evaluated by measuring the GLuc activities in the culture supernatants at 24, 48, and 72 h posttransfection (Fig. 1B) . As shown in Fig. 1C , the GLuc activity increased over time in the cells cotransfected with the minigenomic vRNA and the four plasmids, whereas there was no increase in the GLuc activity in the cells transfected with the vRNA alone or together with the three plasmids. This result suggested that in vitro synthesized EBOV minigenomic vRNA could replicate and transcribe with the help of viral proteins NP, VP35, VP30, and L.
To further improve this EBOV minigenome system, we generated Huh7-4P cells that stably express NP, VP35, VP30, and L ( Fig. 2A) . Huh7 cells were first transfected with pcDNA3.1 expressing L, followed by G418 selection for 3 weeks. The resulting Huh7-L cells were then transduced with three lentiviruses encoding NP, VP35, and VP30, respectively, generating Huh7-4P cells. Expression of the NP, VP35, and VP30 proteins in Huh7-4P cells was confirmed by Western blotting (Fig. 2B) . Due to the lack of an L-specific antibody, the expression of L was verified by reverse transcription-PCR (RT-PCR) (Fig. 2C) . Next, Huh7-4P cells were transfected with the in vitro transcribed minigenomic vRNA, and the GLuc activities in the culture supernatants were measured at the indicated time points after the transfection. As shown in Fig. 2D , the GLuc activity dramatically increased at 12 h posttransfection and reached over 10 6 relative light units (RLU) at 96 h posttransfection. Nevertheless, the levels of the GLuc activities continuously dropped afterward and to below 10 4 RLU on day 19 posttransfection (Fig. 2E) , suggesting that the EBOV minigenome replication and transcription were not stable in the helper cells.
Establishment of the EBOV minigenome replicon cells. Next, we attempted to establish a cell line that could persistently replicate and transcribe the EBOV minigenome. A two-reporter gene system encoding GLuc and a hygromycin (Hyg)-resistant protein separated by autocleavable peptide 2A derived from foot-and-mouth disease virus (FMDV) (13) was inserted into the minigenome (EBOV-GLuc-Hyg) (Fig. 3A) . Upon translation, the fusion protein undergoes self-cleavage to produce the functional GLuc and the hygromycin-resistant protein, which allows quantification of minigenome transcription/replication and selection of the stably replicating minigenome, respectively. In vitro transcribed EBOV-GLuc-Hyg RNA was electroporated into Huh7-4P or Huh7-L cells followed by hygromycin selection for 3 weeks. Crystal violet staining showed that hygromycin-resistant cell colonies could be selected in Huh7-4P cells but not in Huh7-L cells (Fig. 3B ), suggesting that stable replication of the EBOV minigenome was achieved under conditions of hygromycin selection with the help of RNP proteins. The hygromycin-resistant cells were pooled and maintained in the medium containing hygromycin for up to 18 weeks. As shown in Fig. 3C , the GLuc activities in the culture supernatants remained stable for more than 4 months, suggesting that the EBOV minigenome can stably replicate in the replicon cells. We ruled out the possibility of integration of the GLuc-Hyg cassette into the host genome by PCR amplification of GLuc-Hyg gene using the extracted genomic DNA of the replicon cells (data not shown). Comparison of the protein levels of NP, VP35, and VP30 as well as of L mRNA levels between the replicon cells and parental Huh7-4P cells showed that the protein levels were comparable while the L mRNA levels were slightly higher in the replicon cells ( Fig. 3D and E) .
We next analyzed minigenome transcription and replication by determining the levels of 3 types of minigenomic RNA: mRNA, vRNA, and cRNA (complementary to vRNA; genome replication intermediate). To do so, we first developed a new quantitative reverse transcription-PCR (RT-qPCR) method using tagged RT primers ( Fig. 4A and B). Compared to the conventional method using untagged RT primers, the new assay can specifically quantify the minigenomic vRNA/cRNA/mRNA ( Fig. 4C and D) . Next, we compared the transcription and replication efficiencies of the EBOV minigenome in the transient-transfection system (day 3 posttransfection; Fig. 2E ) and in the replicon system by measuring GLuc activities and vRNA/cRNA/mRNA levels. As shown in Fig. 5A and B, levels of GLuc activity and minigenomic mRNA were 10-fold higher in the transiently transfected cells than in the replicon cells. However, EBOV minigenomic cRNA and vRNA levels were about 10-fold and 7-fold higher, respectively, in the replicon cells (Fig. 5C and D) . These results suggested that the replicon cells had much higher levels of active minigenome replication than the transiently transfected cells.
The EBOV minigenome replicon was resistant to IFN treatment. Interferons (IFNs) are important cytokines with broad antiviral activity and are widely used in treating viral infections. To evaluate the anti-EBOV activities of IFNs, we treated the EBOV-GLuc-Hyg replicon cells with alpha IFN (IFN-␣) (type I), IFN-␥ (type II), and IFN-3 (type III) at the indicated doses for 48 h and then measured minigenome mRNA levels. Hepatitis C virus (HCV) replicon Huh7 cells (14) were included as a control. As shown in Fig. 6A to C, the EBOV minigenome was insensitive to IFN treatment whereas HCV replication was efficiently inhibited. The analysis of GLuc activity also confirmed the insensitivity of the EBOV minigenome replicon to IFNs (Fig. 6D) . To determine whether the IFN signaling was intact in the EBOV replicon cells, the mRNA levels of MxA, an interferon-stimulated gene (ISG) product of type I and III IFNs, as well as IFN-␥-inducible protein 10 (IP10), an ISG product of type II IFN, were analyzed by RT-qPCR in the IFN-treated EBOV-GLuc-Hyg replicon, HCV replicon, and naive Huh7 cells. As shown in 6E to G, the induction of these ISGs in the EBOV-GLuc-Hyg replicon was comparable to that in HCV replicon and naive Huh7 cells. The normal IFN signaling in the IFN-␣-treated EBOV replicon cells was also confirmed by Western blotting of protein levels of two other ISG products, MDA5 and RIG-I (Fig. 6H and I) . Together, these results demonstrated that EBOV minigenome replication in the replicon cells was resistant to IFN treatment even though the IFN pathways were intact.
The EBOV minigenome replicon was insensitive to RNA interference. RNA interference has been explored as an antiviral agent, and its potential in restricting EBOV infection has been revealed (15) (16) (17) (18) . Next, we evaluated the anti-EBOV potential of RNA interference using the minigenome replicon. Three short hairpin RNAs (shRNAs) targeting the 3= UTR of EBOV L gene (shL1, shL2, and shL3) were tested (Fig. 7A) . EBOV-GLuc-Hyg cells were transduced with lentiviruses expressing shL1, shL2, or shL3 or a control shRNA (shCTL), respectively, and GLuc activities and EBOV vRNA/cRNA/ mRNA levels were measured on day 7 postransduction. shL3 and shL2 efficiently suppressed EBOV transcription as indicated by the decreased GLuc activity and EBOV mRNA levels ( Fig. 7B and C) . Interestingly, neither shRNA decreased the levels of cRNA and vRNA ( Fig. 7D and E) , suggesting that EBOV replication seemed to be more difficult to suppress than transcription, likely due to cRNP and the viral RNP (vRNP) complex, which protect cRNA and vRNA, respectively. EBOV vRNP displayed strong stability. Next, we attempted to assess the stability of the EBOV minigenome RNP. The EBOV-GLuc-Hyg replicon cell lysates were prepared and incubated at room temperature for up to 6 days, and the levels of minigenomic vRNA, cRNA, and mRNA and cellular GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA at the different time points were quantified by RT-qPCR. Remarkably, while all three EBOV minigenome-derived RNAs were more stable than the cellular mRNA, the minigenomic vRNA displayed the greatest stability, with over 20% remaining intact even after 6 days of incubation (Fig. 8A) . Furthermore, we assessed the stability of EBOV RNP in the presence of exogenously added ribonucleases. The EBOV replicon cell lysates were incubated with RNase A for various time periods prior to the RNA quantification. Consistently, EBOV vRNA displayed the highest stability, with over 25% of the vRNA surviving after 2 h of the RNase A treatment (Fig. 8B) . The RT-qPCR analysis using PCR primers targeting different regions within each RNA confirmed that the minigenomic vRNA was the most stable (data not shown). To rule out the possibility that the different levels of RNase sensitivity were caused by the intrinsic natures of different RNAs, the RNAs were extracted from the EBOV replicon cells to remove all proteins prior to the RNase A digestion. As shown in Fig. 8C , all naked RNAs were equally sensitive to the RNase A digestion. Taken together, our data demonstrated that EBOV minigenomic vRNP displayed extraordinary stability.
DISCUSSION
Various EBOV reverse genetics systems have been developed to allow studies of the EBOV life cycle to be carried out outside the BSL4 setting, such as studies of the EBOV minigenome for viral replication and transcription and studies of the trVLP (transcription-and replication-competent virion-like particle) system for other steps (12, 19) . These EBOV minigenome systems are mostly based on cotransfection of multiple plasmids expressing viral proteins and minigenomes in the same cell. Here we developed an EBOV minigenome replicon that can stably replicate and transcribe the EBOV minigenome. This novel replicon system offers several advantages over the traditional transient-transfection-based minigenome models. First, the replicon system offers a more convenient and efficient tool. The transient-transfection-based system requires delivery of 4 or more plasmids simultaneously into the same cell, which is usually not VP24, and GP can be transfected into EBOV-GLuc-Hyg cells to generate single-round infectious virions. Moreover, Huh7-4P cells stably expressing NP, VP35, VP30, and L can be used as the target cells for trVLP analysis.
Previous studies showed that the optimal EBOV minigenome reporter activity was achieved only when four plasmids encoding RNP proteins were transfected into cells at a certain ratio, suggesting that the EBOV replication and transcription events may be regulated by the stoichiometry of NP, VP35, VP30, and L proteins (5, 12) . The EBOV minigenome replicon cells were selected by antibiotic resistance from unsubcloned Huh7-4P cell populations that likely have a different stoichiometry of these four proteins in each cell. Our results showed that the relative expression levels of NP, VP35, and VP30 were comparable between the selected replicon cells and parental Huh7-4P cells, while the L mRNA levels were slightly higher in the replicon cells ( Fig. 3D and E) . It is possible that the elevated L expression may contribute to active and stable EBOV minigenome replication in the replicon cells. It would be interesting to fine-tune the 4-protein stoichiometry in the replicon cells to further enhance EBOV minigenome replication and transcription.
Tagged strand-specific primers have been used in RT-PCR assays to quantify and/or distinguish specific forms of viral RNA, for example, positive-and negative-stranded were measured at day 7 postransduction. RNA levels were measured by RT-qPCR, and all the data were expressed as percentages of short hairpin control (shCTL) treatment. The error bars represent standard deviations of results of three independent experiments. ns, P Ͼ 0.05. **, P Ͻ 0.01. viral genomes of RNA viruses (20, 21) . A similar method has been developed to quantify the positive strand (mRNA and cRNA) and negative strand (vRNA) of EBOV RNA (22) . In this study, we developed a new tagged-strand-specific primer-based RT-qPCR assay to quantify each of the three types of EBOV RNA (Fig. 4) . Compared to conventional RT-qPCR methods using untagged primers, utilization of tagged strand-specific primers makes it feasible to distinguish and quantify vRNA, cRNA, and mRNA of the EBOV minigenome. Such a method should also be useful in quantifying vRNA/cRNA/mRNA during natural EBOV infection.
The role of IFNs in restricting EBOV infection remains controversial. IFN-␤, used for treatment at an early time postexposure, was effective in prolonging the survival time of rhesus macaques but did not improve the survival rate (23) . Another study revealed that IFN-␥ had significant anti-EBOV effects in vivo (24) . One recent in vitro study found that type I IFNs showed efficacy in pretreatments performed 24 h before viral infection at a low multiplicity of infection (MOI), while IFN-␥ showed even lower efficacy. However, neither IFN showed significant inhibitory activity under conditions of pre- treatment performed only 1 h before infection at a high MOI (25) . These results suggested that the timing and/or types of IFN response could be critical for the control of EBOV. Our results showed that neither type I nor type II nor type III IFN inhibits EBOV minigenome replication, providing new evidence to support the hypothesis that established EBOV infection is less susceptible to IFN treatment. A number of studies have shown that EBOV VP24 can block the downstream signaling pathway of IFNs (26) (27) (28) . Since our EBOV minigenome system does not have VP24, lack of response to IFN treatment in the EBOV replicon raises the possibility of the presence of a putative VP24-independent mechanism to counteract the IFN actions, possibly due to inaccessibility of vRNP/cRNP to the IFN-induced antiviral effectors. More investigations are certainly needed to test this hypothesis.
No EBOV therapy has been approved yet even though some displayed good potential in the animal study (18, 29, 30) . A clinical trial of small interfering RNA (siRNA)-based therapy (TKM-Ebola) was suspended because the results of interim analysis were not encouraging (31) . Our results showed that shRNA (shL2 and shL3) targeting the 3= UTR of EBOV L gene displayed a decent ability to decrease the minigenome mRNA level (Fig. 7) . Nevertheless, despite the fact that the minigenomic cRNA harbors the same target sequences of shL2 and shL3, these shRNAs had little inhibitory effect against cRNA or against its replication template/product, vRNA. The different levels of sensitivity of mRNA and cRNA to RNA interference are likely due to the fact that cRNA exists in viral-protein-bound form (cRNP) in the replicon cells and is protected from siRNA attacks. The ineffectiveness of shRNA with respect to the viral genome has been shown with other negative-strand RNA viruses and has been attributed to the protection provided by RNP (32, 33) .
Our results showed that EBOV minigenome-derived vRNAs and cRNAs were more resistant to ribonucleases than cellular and viral mRNAs, consistent with the notion that viral RNA genome and replication intermediates of negative-stranded RNA viruses were always encapsidated with viral structural proteins and were less susceptible to the nuclease digestion (34) . Interestingly, we found that the minigenomic vRNA was more stable than cRNA despite the fact that the both RNAs were encapsidated and protected in the RNP complex. The different levels of susceptibility to RNase digestion suggest possible differences between vRNP and cRNP with respect to their structures or compositions. Since vRNP exists in the EBOV virion structure, the extraordinary stability of vRNP may reflect the astounding persistence of EBOV virions or genomes in the tissues of convalescent patients (35) (36) (37) or in environment settings (38) (39) (40) (41) . As EBOV persistence has increasingly become a research focus (42), our replicon model may provide a useful tool to analyze the contributions of the vRNP stability to persistent EBOV infection.
In conclusion, we developed a novel EBOV minigenome replicon which, to our knowledge, is the first EBOV cell culture system that can stably replicate and transcribe the EBOV minigenome, providing a useful tool for studying EBOV replication and screening antivirals under BSL2 conditions.
MATERIALS AND METHODS
Cell culture. Huh7 and HEK293T cells (obtained from Stem Cell Bank, Chinese Academy of Sciences) were maintained in Dulbecco's modified Eagle medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum, 10 mM HEPES buffer, 100 U/ml penicillin, 100 mg/ml streptomycin, and 0.1 mM nonessential amino acids (NEAA) at 37°C in a moist environment containing 5% CO 2 . Huh7-L and EBOV-GLuc-Hyg replicon cells were selected with 500 g/ml G418 (Sigma-Aldrich, St. Louis, MO, USA) and 100 g/ml hygromycin (Amresco, Solon, OH, USA), respectively. Huh7-L, Huh7-4P, and HCV replicon Huh7 cells were cultured in DMEM containing 250 g/ml G418, and EBOV-GLuc-Hyg replicon cells were cultured in DMEM containing 100 g/ml hygromycin and split every 3 days at a ratio of 1:5. The viability, growth kinetics, and morphology of EBOV-GLuc-Hyg cells were similar to those of Huh7 cells.
Antibodies. Rabbit polyclonal antibodies against EBOV NP, VP35, and VP30 protein were generated using the following peptides to immunize rabbits: DNDRRNEPSGSTSP (NP), RPVPPSPKIDRGWV (VP35), and QSDNEEASTNPGTC (VP30). Rabbit polyclonal antibodies against MDA5 and RIG-I were from Cell Signaling Technology (Danvers, MA, USA).
